Navigation Links
3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Date:8/15/2011

MENLO PARK, Calif., Aug. 15, 2011 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of George W. Kemble, PhD as Chief Scientific Officer.

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

"We are very pleased to have George as the newest member of the 3-V senior management team," said Merdad V. Parsey, MD, PhD, 3-V's Chief Executive Officer.  "George's extensive experience in drug discovery and development, as well as virology and host-cell biology, brings additional strength to the 3-V team and will further our efforts in this novel area."

Prior to joining 3-V Biosciences, Dr. Kemble was with MedImmune, Inc., a subsidiary of Astra-ZenecaPLC, where he most recently served as Senior Vice President of R&D and Head of Research.  During his tenure, Dr. Kemble was responsible for the research and development of multiple products, including the successful launch of FluMist®, the first innovation in influenza vaccines in over 60 years.  The research organization for which he was responsible included over 700 scientists in Maryland, California and Cambridge, England, with expertise in research biology, lead generation and translational science in the areas of infectious diseases, oncology, inflammatory, respiratory, autoimmune diseases, neuroscience, cardiovascular and gastrointestinal indications.  Dr. Kemble began his research career as a staff scientist at Aviron, which was later acquired by MedImmune.  Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.

"I'm very excited by the important projects we have in front of us," said Dr. Kemble.  "Our approach to combating these pathogens is highly innovative, and I am looking forward to continuing to grow our organization's expertise at developing these impactful medicines."  

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield&Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationStephen R. BradyChief Business Officer650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):